Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Anavex Life Sciences Corp (AVXL)

Add AVXL Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, blanka, 123tom, kevindenver, TomP1, Rubyred77
Search This Board: 
Last Post: 12/13/2017 1:34:18 PM - Followers: 719 - Board type: Free - Posts Today: 98

Anavex Life Sciences Corp (AVXL)

Company website:
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA

CIK:  0001314052

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL


Patent Info:

Clinical Trials:
Recent News:
Company News Releases:
Share Structure:  See SEC filings
Investor Relations:

Marketing Details:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXL News: Annual Report (10-k) 12/11/2017 05:17:35 PM
AVXL News: Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs 12/11/2017 07:00:00 AM
AVXL News: Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of... 11/21/2017 07:00:00 AM
AVXL News: Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington... 11/08/2017 07:00:00 AM
AVXL News: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clini... 11/04/2017 03:30:00 PM
#133249  Sticky Note Fact: the company continues to use unambiguous polarbear77 12/07/17 12:00:43 PM
#131122  Sticky Note Has Anavex progressed too slowly and not kept Investor2014 11/20/17 07:44:47 AM
#129044  Sticky Note People seem to always lose track of the dadofmarcmax 11/06/17 10:58:33 AM
#116985  Sticky Note Anavex Life Sciences Corp. - Things To Know. nobrainerstocks 08/24/17 06:32:49 AM
#103034  Sticky Note To answer your good questions. falconer66a 04/26/17 10:18:09 AM
#134181   Total hogwash - XenaLives 12/13/17 02:01:10 PM
#134180   That is nothing but total BS. Missling ohsaycanyousee82 12/13/17 02:00:42 PM
#134179   what you are saying is that Missling was OFP 12/13/17 01:34:18 PM
#134178   I hope you are right it will only attilathehunt 12/13/17 01:25:33 PM
#134176   Thanks - I enrolled a year back. raja48185 12/13/17 01:18:59 PM
#134175   That's a fair speculation to have the P3 kevindenver 12/13/17 01:10:55 PM
#134174   Ok so what you are saying is that anders2211 12/13/17 01:10:49 PM
#134173   Once the trial starts (IMO) it will take anders2211 12/13/17 01:07:12 PM
#134172   Once the trial starts (IMO) it will take attilathehunt 12/13/17 01:01:08 PM
#134171   Thanks "sparky"! Here is a link for those kevindenver 12/13/17 12:58:05 PM
#134170 LakeshoreLeo1953 12/13/17 12:56:58 PM
#134169   Perhaps the P2 legwork will be done in XenaLives 12/13/17 12:55:45 PM
#134168   Ditto's here, I have hope the Michael J kevindenver 12/13/17 12:48:24 PM
#134167   Has anyone heard anything from the Noble road show?? riaguy 12/13/17 12:45:19 PM
#134166   We all hope before Christmas. Penny Double 12/13/17 12:29:54 PM
#134165   Can you please reason why you think there OFP 12/13/17 12:22:08 PM
#134164   Thx, the main benefits I see with 21 kevindenver 12/13/17 12:21:51 PM
#134163   According to some, their charts show that tax ExtremelyBullishZig 12/13/17 12:01:24 PM
#134161   I really dont think you are negative on anders2211 12/13/17 11:56:36 AM
#134160   Always worried we'd be squashed, like the stories baltimorebullet 12/13/17 11:44:45 AM
#134159   Anders - Whats with that? If the FDA attilathehunt 12/13/17 11:44:12 AM
#134158   Hi Mycroft. anders2211 12/13/17 11:34:13 AM
#134157   Great point Not having all our eggs in one Cbdpotential 12/13/17 11:25:51 AM
#134156   I gather Missling filed for both Rett and Investor2014 12/13/17 11:25:06 AM
#134155   Dead wrong. The PD trial was always intended blu_1 12/13/17 11:22:21 AM
#134154   Yes I agree with all you have said anders2211 12/13/17 11:20:15 AM
#134153   I think it's great because my paranoid side baltimorebullet 12/13/17 11:17:55 AM
#134152   will expand position if this goes to 3 bucks nidan7500 12/13/17 11:15:40 AM
#134151   Very interesting speculation except the last sentence. GLTY sage4 12/13/17 11:13:55 AM
#134150   Please do not put me down its very anders2211 12/13/17 11:13:50 AM
#134149   Okay I’m back in and will expand position noretreat 12/13/17 11:10:04 AM
#134148   Missling stated the Rett trial could start this attilathehunt 12/13/17 11:00:12 AM
#134147   As soon as the science can't be ignored Cbdpotential 12/13/17 10:58:06 AM
#134146   Basparks: Thanks so much for that enlightening bennyboy1 12/13/17 10:52:19 AM
#134145   Look OFP I understand your cautionI don't think OFP 12/13/17 10:36:50 AM
#134144   Tom..they may be---do you have proof they are TomP1 12/13/17 10:34:48 AM
#134143   Can someone explain why the co. is trading TomP1 12/13/17 10:32:13 AM
#134142   Tom..they may be---do you have proof they are plexrec 12/13/17 10:28:21 AM
#134141   Look OFP I understand your caution. But lets anders2211 12/13/17 10:27:28 AM
#134140   My April's fools prediction could still turn out Investor2014 12/13/17 10:27:10 AM
#134139   I'm waiting for $2s. It may or may Gator328 12/13/17 10:25:02 AM
#134138   Seems so... Great opportunity though imo I highly doubt this Cbdpotential 12/13/17 10:24:53 AM
#134136   One has to recognise that not all European Investor2014 12/13/17 10:18:26 AM
#134135   Ofcourse Europe is much bigger than the European anders2211 12/13/17 10:17:38 AM
#134134   he thinks BIIB is still testing.... TomP1 12/13/17 10:16:39 AM
#134133   But, getting past regulatory hurdles is going to anders2211 12/13/17 10:08:26 AM
#134132   thank you, andres2211, but here what I got: samk 12/13/17 10:06:31 AM
#134130 AVXL IS ridic anders2211 12/13/17 09:57:52 AM
#134129   Which is exactly what the shorts are hoping for. Investor2014 12/13/17 09:48:45 AM
#134128   From the Tom Bishop article this morning--" Nonetheless, plexrec 12/13/17 09:48:39 AM